GCG and diabetes mellitus: Mads Krogsgaard Thomsen, at the time R&D executive in the Diabetes Care Division of Novo Nordisk, undertook the initiative to synthesize long-acting GLP-1 analogues (Fig. 1), and the first GLP-1 analogue brought into clinical development was liraglutide, a once-daily injection.